Vsg-based vaccination and antibody generation platform for the treatment of diseases

US12285474B2 · kind B2 · utility

Assignee

• DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS · DE

Inventors

• Fotini Nina Papavasiliou · Heidelberg, DE
• Hamidreza Hashemi · Heidelberg, DE
• Gianna Triller · Heidelberg, DE
• Erec Stebbins · Heidelberg, DE
• Aubry Miller · San Francisco, US
• Andreas Baumann · Münsingen, CH

Key dates

• Filing date: Oct 24, 2019
• Grant date: Apr 29, 2025
• Expiry date: Jun 7, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/6075
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is based on a platform for vaccination and/or antibody generation. The invention is based on the display of small molecular immunogenic compounds on the coat of variant surface glycoproteins (VSG) on trypanosomes which results in a highly effective immune response when used as a vaccine or in immunization for antibody production. The herein disclosed antigenic particles are applicable for producing antibodies or can be directly used as vaccines for the treatment of various medical conditions. Most preferably the invention relates to the VSG based vaccines specific for dependency causing substances for the treatment of addiction or avoidance of adverse events during drug abuse. Other applications include methods and uses involving the disclosed compounds and compositions for a treatment or prevention of cancer, infectious disease, contagious neurodegenerative diseases, non-communicable disorders (e.g. certain neurodegenerative diseases, allergies) and any condition or industrial use for which an immune response from vaccination or antibody use would be desirable.